INMB
Inmune Bio, Inc.
Key Financials
Operating Income
$-47383000
↓ 11.1%
Revenue
$50000
↑ 257.1%
Net Income
$-45933000
↓ 9.2%
Total Assets
$32.4M
↓ 18.2%
EPS (Diluted)
$-1.86
↑ 11.8%
Cash & Equivalents
$24.8M
↑ 18.3%
Shareholders' Equity
$23.5M
↓ 26.7%
Long-term Debt
$15.0M
0.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/23/2026 | View on SEC |
| 3 | 9/23/2026 | View on SEC |
| 4 | 9/17/2026 | View on SEC |
| 3 | 9/16/2026 | View on SEC |
| 8-K | 9/14/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 7/31/2026 | View on SEC |
| 4 | 7/7/2026 | View on SEC |
| 4 | 7/7/2026 | View on SEC |
| 4 | 7/7/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | INMB |
| Company Name | Inmune Bio, Inc. |
| CIK | 1711754 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | 8589643720 |